Cognitive Impairment - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cognitive Impairment - Pipeline Review, H2 2015, provides an overview of the Cognitive Impairments therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=124187/cognitive-impairment-pipeline-review-h2-2015
To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=124187/cognitive-impairment-pipeline-review-h2-2015
Table of Contents
Table of Contents
2 List of Tables
7 List of Figures
10 Global Markets Direct Report Coverage
10 Cognitive Impairment Overview
11 Therapeutics Development
12 Pipeline Products for Cognitive Impairment - Overview
12 Pipeline Products for Cognitive Impairment - Comparative Analysis
13 Cognitive Impairment - Therapeutics under Development by Companies
14 Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
19 Cognitive Impairment - Pipeline Products Glance
21 Late Stage Products
21 Clinical Stage Products
22 Early Stage Products
23 Cognitive Impairment - Products under Development by Companies
24 Cognitive Impairment - Products under Investigation by Universities/Institutes
31 Cognitive Impairment - Companies Involved in Therapeutics Development
32 AbbVie Inc.
32 Actinogen Limited
33 Addex Therapeutics Ltd
34 Amarantus Bioscience Holdings, Inc.
35 Astellas Pharma Inc.
36 AstraZeneca Plc
37 Avineuro Pharmaceuticals, Inc.
38 Avraham Pharmaceuticals Ltd.
39 Boehringer Ingelheim GmbH
40 Bristol-Myers Squibb Company
41 Cardax Pharmaceuticals, Inc.
42 CereSpir Incorporated
43 Cognition Therapeutics, Inc.
44 D-Pharm Ltd. 45 Eisai Co., Ltd.
46 Eli Lilly and Company
47 Evotec AG
48 F. Hoffmann-La Roche Ltd.
49 FORUM Pharmaceuticals Inc.
50 H. Lundbeck A/S
51 Heptares Therapeutics Limited
52 Impel NeuroPharma, Inc.
53 Intra-Cellular Therapies, Inc.
54 Iproteos S.L.
55 Merck & Co., Inc.
56 Mnemosyne Pharmaceuticals, Inc.
57 Neuralstem, Inc.
58 Neuron Biopharma SA
59 Octapharma AG 60 Omeros Corporation
61 Pacific Northwest Biotechnology, LLC
62 Panacea Pharmaceuticals, Inc.
63 Pfizer Inc.
64 Pherin Pharmaceuticals, Inc.
65 Sage Therapeutics
66 Saniona AB
67 Shire Plc
68 Siena Biotech S.p.A.
69 SK Biopharmaceuticals Co., Ltd.
70 Sunovion Pharmaceuticals Inc.
71 Suven Life Sciences Ltd.
72 Takeda Pharmaceutical Company Limited
73 Teva Pharmaceutical Industries Limited 74 Upsher-Smith Laboratories, Inc.
75 Vanda Pharmaceuticals Inc.
76 Vicore Pharma AB
77 Virogenomics, Inc.
78 Cognitive Impairment - Therapeutics Assessment
79 Assessment by Monotherapy Products
79 Assessment by Target
80 Assessment by Mechanism of Action 88 Assessment by Route of Administration
95 Assessment by Molecule Type
98 Drug Profiles
101 A-431404 - Drug Profile
101 ADX-92639 - Drug Profile
102 AN-761 - Drug Profile
103 AP-61 - Drug Profile
104 AQW-051 - Drug Profile
105 ASP-4345 - Drug Profile
106 ASP-5736 - Drug Profile
107 AUT-1 - Drug Profile
108 AUT-6 - Drug Profile
109 AUT-9 - Drug Profile
110 AVL-3288 - Drug Profile
111 AVN-211 - Drug Profile
112 BAN-2401 - Drug Profile
113 BCA-909 - Drug Profile
115 BI-409306 - Drug Profile
117 BNC-375 - Drug Profile
119 C-21 - Drug Profile
120 CDX-085 - Drug Profile
122 CSP-1103 - Drug Profile
124 CT-0093 - Drug Profile
126 DAOI-B - Drug Profile
127 DP-NDD - Drug Profile
128 Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
129 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile
130 DSP-3748 - Drug Profile
131 E-1R - Drug Profile
132 eltoprazine - Drug Profile
133 encenicline hydrochloride - Drug Profile
135 erteberel - Drug Profile
138 EVT-501 - Drug Profile
139 HTL-9936 - Drug Profile
140 IB-AD - Drug Profile
141 IC-041 - Drug Profile
142 idursulfase - Drug Profile
143 immune globulin (human) - Drug Profile
145 insulin (human) - Drug Profile
148 IPR-001 - Drug Profile
149 IPR-088 - Drug Profile
150 IPR-19 - Drug Profile
151 irdabisant - Drug Profile
152 ITI-214 - Drug Profile
153 JAY-22233 - Drug Profile
154 ladostigil tartrate - Drug Profile
156 levetiracetam - Drug Profile
158 LS-1137 - Drug Profile
159 LUAF-64280 - Drug Profile
160 LY-3002813 - Drug Profile
161 NPS-0158 - Drug Profile
162 NS-9283 - Drug Profile
163 NSI-189 - Drug Profile
165 NSP-0163 - Drug Profile
167 NST-0037 - Drug Profile
168 NST-0076 - Drug Profile 169 NST-0078 - Drug Profile
170 O-1966 - Drug Profile 171 PAN-811 - Drug Profile
172 PF-04958242 - Drug Profile
174 PH-15 - Drug Profile
176 PNU-120596 - Drug Profile
177 RO-4938581 - Drug Profile
178 roflumilast - Drug Profile
179 RTL-551 - Drug Profile
182 SEN-15924 - Drug Profile
184 sepranolone - Drug Profile
185 SKL-15508 - Drug Profile
188 SKL-A4R - Drug Profile
189 Small Molecule 1 for Cognitive Impairment - Drug Profile
190 Small Molecule 10 for Cognitive Impairment - Drug Profile
191 Small Molecule 11 for Cognitive Impairment - Drug Profile
192 Small Molecule 12 for Cognitive Impairment - Drug Profile
193 Small Molecule 2 for Cognitive Impairment - Drug Profile
194 Small Molecule 3 for Cognitive Impairment - Drug Profile
195 Small Molecule 4 for Cognitive Impairment - Drug Profile
196 Small Molecule 5 for Cognitive Impairment - Drug Profile
197 Small Molecule 6 for Cognitive Impairment - Drug Profile
198 Small Molecule 7 for Cognitive Impairment - Drug Profile
199 Small Molecule 8 for Cognitive Impairment - Drug Profile
200 Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile
201 Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile
202 Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile
203 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile
204 Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile
205 Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
206 Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer - Drug Profile
207 Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile
208 Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile
209 Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile
210 Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile 211 Small Molecules to Agonize GABA alpha 5 for Cognitive Impairment - Drug Profile
212 Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile
213 Small Molecules to Agonize NMDA2B for CIAS - Drug Profile
214 Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile
216 SUVN-501 - Drug Profile
218 SUVN-502 - Drug Profile
219 SUVN-507 - Drug Profile
221 SUVN-512 - Drug Profile
222 SUVN-976 - Drug Profile
223 TAK-058 - Drug Profile
224 TAK-915 - Drug Profile
225 tropisetron hydrochloride - Drug Profile
226 UE-2343 - Drug Profile 227 VU-0092273 - Drug Profile
228 xamoterol fumarate - Drug Profile
229 Cognitive Impairment - Recent Pipeline Updates
230 Cognitive Impairment - Dormant Projects
258 Cognitive Impairment - Discontinued Products
265 Cognitive Impairment - Product Development Milestones
266 Featured News & Press Releases
276 Methodology 276 Coverage
276 Secondary Research
276 Primary Research
276 Expert Panel Validation
276 Contact Us
276 Disclaimer 277
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.